SCHEMBL2081996

SCHEMBL2081996

CC(C)(C)OC(=O)NC1([C@@H]2CCN(c3ccc4c(=O)c(C(=O)O)cn([C@@H]5C[C@@H]5F)c4c3Cl)C2)CC1

nearest known ligand 0.58

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 1/20 0.58
KCNH2 Q12809 7/20 0.39
ALDH1A1 P00352 3/20 0.37
POLB P06746 1/20 0.37
CHRM2 P08172 1/20 0.37
CHRM1 P11229 1/20 0.37
OPRM1 P35372 1/20 0.37
OPRD1 P41143 1/20 0.37
TOP1 P11387 2/20 0.32
CNR2 P34972 2/20 0.31
PIK3CG P48736 1/20 0.31
KDM4E B2RXH2 2/20 0.30
MAPK8 P45983 1/20 0.30
LPL P06858 1/20 0.30
LIPG Q9Y5X9 1/20 0.30
LMNA P02545 1/20 0.30
MAPT P10636 1/20 0.30
HPGD P15428 1/20 0.30
HSD17B10 Q99714 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2081994 1.00 CYP3A4 (0.58) CYP3A4KCNH2ALDH1A1POLBCHRM2
SCHEMBL482753 0.91 CYP3A4 (0.72) CYP3A4KCNH2ALDH1A1POLBOPRM1
SCHEMBL2078716 0.88 CYP3A4 (0.70) CYP3A4KCNH2ALDH1A1POLBOPRM1
SCHEMBL2078715 0.88 CYP3A4 (0.70) CYP3A4KCNH2ALDH1A1POLBOPRM1
SCHEMBL2081212 0.82 CYP3A4 (0.77) CYP3A4KCNH2ALDH1A1POLBCHRM2
SCHEMBL2081209 0.82 CYP3A4 (0.77) CYP3A4KCNH2ALDH1A1POLBCHRM2
SCHEMBL2081946 0.82 CYP3A4 (0.47) CYP3A4KCNH2ALDH1A1POLBCHRM2
SCHEMBL5260065 0.82 CYP3A4 (0.47) CYP3A4KCNH2ALDH1A1POLBCHRM2
SCHEMBL2081948 0.82 CYP3A4 (0.47) CYP3A4KCNH2ALDH1A1POLBCHRM2
SCHEMBL3590072 0.81 CYP3A4 (0.57) CYP3A4KCNH2ALDH1A1POLBOPRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7902226-B2 Dehalogeno-compounds DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2011-03-08 US disclosed
EP-1336611-B1 DEHALOGENO COMPOUNDS DAIICHI SEIYAKU CO (JP) 2007-09-05 EP disclosed
US-20070123560-A1 Dehalogeno-compounds DAIICHI PHARMACEUTICAL CO., LTD. 2007-05-31 US disclosed
US-20040063754-A1 Dehalogeno compounds DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2004-04-01 US disclosed
EP-1336611-A1 DEHALOGENO COMPOUNDS DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2003-08-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040063754-A1 Dehalogeno compounds DEK, PGLS, RPS27L CYP3A4 198/4885KCNH2 1597/4885ALDH1A1 2494/4885
US-20070123560-A1 Dehalogeno-compounds DEK, RPS27L, POLL CYP3A4 277/4885KCNH2 1059/4885ALDH1A1 3424/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.